0
Correspondence |

ResponseResponse FREE TO VIEW

Ivan F. N. Hung, MD; Kwok-Yung Yuen, MD
Author and Funding Information

From the Department of Medicine (Dr Hung) and the Department of Microbiology (Dr Yuen), University of Hong Kong.

Correspondence to: Kwok-Yung Yuen, MD, Department of Microbiology, University of Hong Kong, Room 423, Pathology Bldg, Queen Mary Hospital Compound, 102 Pokfulam Rd, Hong Kong, China; e-mail: kyyuen@hkucc.hku.hk


Financial/nonfinancial disclosures: The authors have reported to CHEST that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details.


Chest. 2013;144(2):712-713. doi:10.1378/chest.13-0571
Text Size: A A A
Published online
To the Editor:

We thank Drs Joob and Wiwanitkit for their comments on our article on hyperimmune IV immunoglobulin (H-IVIG) treatment.1 Based on the prospective, multicenter, randomized, double-blind nature of our study and the effect of the H-IVIG on the viral load and cytokines, we believe that this study is important in the management of patients with severe 2009 influenza A(H1N1) infection in which no effective treatment other than supportive care is available. The 17 patients who underwent H-IVIG treatment in this study showed no adverse effects of anaphylaxis, hypotension, or rash, with excellent long-term outcome upon follow-up for the 12 patients who survived. As mentioned in the “Discussion,” the safety of the H-IVIG is further improved by fractionation with additional pathogen reduction steps. Nevertheless, we agree with Drs Joob and Wiwanitkit that a future study of a larger scale based upon this study on H-IVIG would be necessary to determine the cost-effectiveness of this new therapeutic option.

References

Hung IFN, To KKW, Lee C-K, et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest. 2013;144(2):464-473.
 

Figures

Tables

References

Hung IFN, To KKW, Lee C-K, et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest. 2013;144(2):464-473.
 
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543